We are live on ! Find out more
Cambridge Investment Research Advisors

Cambridge Investment Research Advisors Portfolio holdings

AUM $44.6B
1-Year Est. Return 28.94%
This Fund
S&P 500
This Quarter Est. Return
-4.68%
1 Year Est. Return
+28.94%
3 Year Est. Return
+82.62%
5 Year Est. Return
+90.41%
10 Year Est. Return
+293.66%
AUM
$17.7B
AUM Growth
-$815M
Cap. Flow
+$169M
Cap. Flow %
0.95%
Top 10 Hldgs %
18.06%
Holding
3,210
New
168
Increased
1,509
Reduced
1,241
Closed
160

Sector Composition

Rank Sector Weight
1 Technology 8.86%
2 Financials 4.76%
3 Consumer Discretionary 4.5%
4 Healthcare 4.18%
5 Consumer Staples 2.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LFMD icon
2976
LifeMD
LFMD
$159M
$30K ﹤0.01%
15,000
-1,204
-7% -$2.87K
TRX icon
2977
TRX Gold Corp
TRX
$360M
$30K ﹤0.01%
76,300
+5,000
+7% +$2.19K
CLSD
2978
DELISTED
Clearside Biomedical
CLSD
$29K ﹤0.01%
1,733
GNSS icon
2979
Genasys
GNSS
$77.4M
$29K ﹤0.01%
10,410
RNXT icon
2980
RenovoRx
RNXT
$50.5M
$29K ﹤0.01%
14,400
VKTX icon
2981
Viking Therapeutics
VKTX
$3.97B
$29K ﹤0.01%
10,814
-499
-4% -$1.63K
DHC
2982
Diversified Healthcare Trust
DHC
$2.02B
$27K ﹤0.01%
+27,107
New +$43.5K
GEVO icon
2983
Gevo
GEVO
$391M
$27K ﹤0.01%
11,920
+1,000
+9% +$2.79K
SAN icon
2984
Banco Santander
SAN
$211B
$27K ﹤0.01%
11,711
-35
-0.3% -$88
AIM
2985
AIM ImmunoTech
AIM
$7.13M
$27K ﹤0.01%
472
+5
+1% +$350
PRTY
2986
DELISTED
Party City Holdco Inc.
PRTY
$26K ﹤0.01%
16,332
ISUN
2987
DELISTED
iSun, Inc. Common Stock
ISUN
$25K ﹤0.01%
11,202
+832
+8% +$2.56K
SENS icon
2988
Senseonics Holdings Inc
SENS
$419M
$24K ﹤0.01%
916
+50
+6% +$1.53K
VXRT
2989
DELISTED
Vaxart
VXRT
$24K ﹤0.01%
+10,832
New +$37.4K
TRVN
2990
DELISTED
Trevena, Inc.
TRVN
$24K ﹤0.01%
249
+144
+137% +$22.1K
ADNWW
2991
DELISTED
Advent Technologies Holdings Warrant
ADNWW
$22K ﹤0.01%
38,500
-10,000
-21% -$5.54K
AXDX
2992
DELISTED
Accelerate Diagnostics
AXDX
$22K ﹤0.01%
+1,452
New +$24K
RAVE icon
2993
RAVE Restaurant Group
RAVE
$43.9M
$22K ﹤0.01%
15,499
DTIL icon
2994
Precision BioSciences
DTIL
$205M
$21K ﹤0.01%
541
+33
+6% +$1.57K
OGI
2995
Organigram Holdings
OGI
$182M
$20K ﹤0.01%
5,788
-45
-0.8% -$188
VRPX
2996
DELISTED
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
$20K ﹤0.01%
67
VLDR
2997
DELISTED
Velodyne Lidar, Inc. Common Stock
VLDR
$20K ﹤0.01%
21,061
-975
-4% -$1.14K
BDTX icon
2998
Black Diamond Therapeutics
BDTX
$121M
$19K ﹤0.01%
11,231
LIDR icon
2999
AEye
LIDR
$61.4M
$19K ﹤0.01%
+573
New +$32K
SHCR
3000
DELISTED
Sharecare, Inc. Class A Common Stock
SHCR
$19K ﹤0.01%
10,220

Similar funds

Cambridge Investment Research Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Cambridge Investment Research Advisors held 3,210 positions worth $17.7B, down 4.4% from $18.6B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Cambridge Investment Research Advisors's Q3 2022 filing shows 168 new, 1,509 increased, 1,241 reduced and 160 closed positions. Its largest new stake was JPMorgan BetaBuilders US Equity ETF: 201,011 shares worth $12.9M. The largest sale was iShares S&P Small-Cap 600 Value ETF, an estimated $46M.

By sector, the portfolio is most concentrated in Technology at 8.9% of assets, down from 9% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Cambridge Investment Research Advisors's largest Q3 2022 buy was JPMorgan BetaBuilders US Equity ETF: 201,011 shares worth $12.9M.
  • Cambridge Investment Research Advisors added most to First Trust Enhanced Short Maturity ETF in Q3 2022, an estimated $41.2M increase.
  • Cambridge Investment Research Advisors's biggest Q3 2022 reduction was iShares S&P Small-Cap 600 Value ETF, cutting an estimated $46M.
  • Cambridge Investment Research Advisors fully exited Invesco DB Energy Fund in Q3 2022, selling an estimated $5.88M.
  • Cambridge Investment Research Advisors's ten largest holdings make up 18% of its $17.7B portfolio in Q3 2022.
  • Cambridge Investment Research Advisors opened 168 new positions and closed 160 in Q3 2022.
  • Cambridge Investment Research Advisors's portfolio value fell 4.4% quarter-over-quarter to $17.7B.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2022, filed 17 Oct 2022.